

**American College of Radiology®  
ACR Appropriateness Criteria®**

**Clinical Condition:** Follow-up of Lower-Extremity Arterial Bypass Surgery

**Variant 1:** Infrainguinal vein graft. Asymptomatic patient. Surveillance.

Radiologic Procedure	Rating	Comments	RRL*
Ankle brachial index and single level pulse volume recording	9		O
US lower extremity with Doppler	8		O
MRA lower extremity without and with contrast	3		O
MRA lower extremity without contrast	2		O
CTA lower extremity with contrast	2		⊕⊕⊕
Arteriography lower extremity	1		⊕⊕⊕
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			*Relative Radiation Level

**Variant 2:** Infrainguinal vein graft. Pain and/or swelling and/or ischemia and/or abnormal ankle brachial index (ABI).

Radiologic Procedure	Rating	Comments	RRL*
Ankle brachial index and single level pulse volume recording	9		O
Arteriography lower extremity	9		⊕⊕⊕
US lower extremity with Doppler	8		O
MRA lower extremity without and with contrast	8	See statement regarding contrast in text under "Anticipated Exceptions."	O
CTA lower extremity with contrast	8		⊕⊕⊕
MRA lower extremity without contrast	5		O
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			*Relative Radiation Level

## FOLLOW-UP OF LOWER-EXTREMITY ARTERIAL BYPASS SURGERY

Expert Panel on Vascular Imaging: Bill S. Majdalany MD<sup>1</sup>; Frank J. Rybicki, MD, PhD<sup>2</sup>; Karin E. Dill, MD<sup>3</sup>; Dennis F. Bandyk, MD<sup>4</sup>; Christopher J. Francois, MD<sup>5</sup>; Marie D. Gerhard-Herman, MD<sup>6</sup>; Michael Hanley, MD<sup>7</sup>; Sanjeeva P. Kalva, MD<sup>8</sup>; Emile R. Mohler III, MD<sup>9</sup>; John M. Moriarty, MB, BCh<sup>10</sup>; Isabel B. Oliva, MD<sup>11</sup>; Matthew P. Schenker, MD<sup>12</sup>; Clifford Weiss, MD.<sup>13</sup>

### **Summary of Literature Review**

#### **Introduction/Background**

Peripheral arterial occlusive disease (PAOD) affects nearly 8 million patients in the United States and up to 20% of patients in the primary care setting. Increased prevalence among older patients, diabetics, and those with end-stage renal disease is well established. This disease progresses from an asymptomatic process to claudication and then to critical limb ischemia [1]. Over the past few decades, the increasing variety of pharmacological agents and the improving efficacy of endovascular interventions for PAOD have led to fewer lower-extremity arterial bypass procedures, according to national trend studies, with comparable quality-of-life and amputation-free survival outcomes. Lower-extremity arterial bypass procedures are also used in patients who are technically unsuitable candidates for aggressive medical management or endovascular revascularization [2-5].

A lower-extremity arterial bypass is categorized by the anastomoses of the created conduit and use of autogenous vein, prosthetic graft, or biologic graft. Historically, autogenous, greater saphenous venous grafts are preferred over prosthetic or biologic grafts, particularly for below-the-knee bypass. Prosthetic grafts are the mainstay when the greater saphenous vein has been previously harvested or is currently unsuitable; biologic graft use is limited to infected fields. Studies comparing primary patency, secondary patency, and limb-salvage rates of graft materials further support the preference for autogenous bypass graft [6-9].

Bypass failure stems from the development of stenoses within or adjacent to the graft and, ultimately, thrombosis, if left uncorrected [10,11]. Although early bypass failures reflect technical errors in placement, later failures are usually due to intimal hyperplasia or the progression of underlying disease at anastomotic sites. During the first postoperative year, up to 30% of venous grafts develop stenoses [12]. There is evidence suggesting that repair of these stenoses, by either surgical or endovascular means, extends the patency of venous bypass grafts [13-18]. Moreover, patency following revision of a thrombosed vein graft is inferior to patency following revision of a stenotic graft prior to thrombosis [19].

There is strong evidence that using intraoperative, duplex ultrasound (US) during the graft reduces early graft failures [12,20]. In fact, the most sensitive predictor of subsequent graft stenosis formation is an abnormal duplex US during initial surgery [17].

Previously, postsurgical surveillance was limited to clinical observation of recurring symptoms, ABI measurement, and segmental volume recordings [21,22]. Over the past 2 decades, use of routine duplex US for asymptomatic patients following infrainguinal bypass has gained acceptance. Further imaging may be warranted for anatomic mapping prior to open surgical or endovascular intervention for dysfunctional grafts as identified by clinical symptoms or duplex US.

Digital subtraction angiography (DSA) remains the standard imaging modality reference for precise evaluation of the severity, location, and character of graft stenoses as well as evaluation of the quality of native vessels proximal and distal to the graft prior to reintervention. More recently, magnetic resonance angiography (MRA) and computer tomography angiography (CTA) have become more accepted as noninvasive imaging substitutes for DSA. These studies may be warranted prior to urgent intervention even in cases of an acutely threatened limb after bypass graft failure.

<sup>1</sup>Research Author, Brigham and Women's Hospital, Boston, Massachusetts. <sup>2</sup>Principal Author and Panel Chair, Brigham and Women's Hospital, Boston, Massachusetts. <sup>3</sup>Panel Vice-chair, University of Chicago, Chicago, Illinois. <sup>4</sup>University of San Diego, La Jolla, California, Society of Vascular Surgeons. <sup>5</sup>University of Wisconsin, Madison, Wisconsin. <sup>6</sup>Brigham and Women's Hospital, Boston, Massachusetts, American College of Cardiology. <sup>7</sup>University of Virginia, Charlottesville, Virginia. <sup>8</sup>Massachusetts General Hospital, Boston, Massachusetts. <sup>9</sup>University of Pennsylvania, Philadelphia, Pennsylvania, American College of Cardiology. <sup>10</sup>University of California Los Angeles, Los Angeles, California. <sup>11</sup>Yale University School of Medicine, New Haven, Connecticut. <sup>12</sup>Brigham and Women's Hospital, Boston, Massachusetts. <sup>13</sup>Johns Hopkins Bayview Medical Center, Baltimore, Maryland.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: Department of Quality & Safety, American College of Radiology, 1891 Preston White Drive, Reston, VA 20191-4397.

## **Ultrasound**

Vein graft surveillance is most commonly performed using duplex US, which has been a method of vein graft surveillance for more than 20 years [23-25].

In clinical practice, duplex US of the bypass conduit is routinely performed at the time of implantation and at regular intervals for surveillance. The technique involves the sequential study of a graft from the proximal to distal anastomosis, with measurement of peak systolic flow velocity (PSFV) and peak systolic flow velocity ratio (PSFVR), which is the ratio of peak systolic velocity to the systolic velocity in the adjacent normal segment. There is evidence to suggest that PSFVR is the most sensitive indicator of a graft stenosis [26-28]. A PSFVR of >2.0–2.5 is often considered representative of a significant stenosis, although some reports suggest a higher value of 3.0–3.5 is a more appropriate threshold for intervention. Other values that can signify a graft stenosis are a PSFV >200 cm/sec at any point in the graft or a midgraft PSFV <45 cm/sec, which may indicate high outflow resistance (suggesting progressive atherosclerosis in the runoff vessels). However, low PSFV can also be present in normal large-caliber vein grafts. Additionally, phase-sensitive US speckle tracking is being studied as a potential means for assessing local wall strain to detect neointimal hyperplasia [29].

No large, randomized, controlled trials support the use of duplex US for either autologous or prosthetic graft surveillance. Moreover, several studies have reached different conclusions. Separate publications by Ferris, Hobbs, Mofidi, and Wilson [30-33] reported that intraoperative, predischarge, and early surveillance duplex US can detect technical problems in grafts at higher risk for future stenoses or occlusions. The Lundell et al [34] study of 165 grafts showed a significant benefit in assisted primary and secondary patency for autologous grafts at 3 years but no benefit in patency for the surveillance of prosthetic grafts. Additionally, a large, nonrandomized study of 615 bypasses found significant improvement in secondary patency and limb salvage for grafts followed by duplex US and ABI when compared with clinical surveillance alone [35].

However, other trials comparing duplex US surveillance versus clinical follow-up of lower-extremity bypass grafts have reached contrary conclusions. A multicenter prospective trial of 594 patients was randomized into a clinical or duplex US follow-up group for 18 months [36]. The primary, primary assisted, and secondary patency rates were nearly identical for both groups (69%, 76%, 80% versus 67%, 76%, 79%, respectively), but the diagnostic costs were significantly higher for the US group. The investigators concluded that using US for routine lower-extremity bypass graft surveillance showed no additional health benefit, but it incurred greater cost. Additionally, multiple authors have reported that duplex US does not enhance lower-extremity arterial bypass graft patency, particularly for prosthetic grafts [37-40].

## **Digital Subtracted Angiography**

Although DSA remains the gold standard for diagnosing PAOD prior to reintervention, it generally plays no role in surveillance of otherwise well-functioning grafts [41,42]. Access-site hematoma, arterial dissection, and thrombosis are known local complications that result from the procedure and occur in up to 8% of patients. Serious systemic complications are also possible. These occur less frequently with increasing operator experience [43,44].

## **Magnetic Resonance Angiography**

Contrast-enhanced MRA is a widely available and commonly used noninvasive and low-risk examination that provides a highly accurate, sensitive, and specific evaluation of the vasculature [45-53]. At present, contrast-enhanced MRA shows an increased ability to properly evaluate bypass grafts and bypass graft inflow and outflow vessels [54-58]. Studies by Reid et al [59], Bertschinger et al [60], and Meissner et al [61] confirmed excellent sensitivity and specificity with MRA use, with the latter study also detecting additional stenoses not seen on US but ultimately confirmed by DSA. Studies using high-resolution, 3-D fast-spin echo techniques have accurately measured inner volumes of bypass grafts and elucidated bypass graft layers, which can be useful in further prospective studies of graft maturation [62-64]. Additionally, new gadolinium-based contrast agents that have higher relaxivity are in development and promise an improved diagnostic performance, particularly in distal vessels [65-71].

Given the growing concerns about nephrogenic systemic fibrosis research of low-dose and nonenhanced MRA is increasing [72,73]. Preliminary studies at 3.0T, with low-dose contrast, have focused on high spatial resolution using dedicated multichannel array coils and accelerated parallel acquisition and continuous table movement with improved spatial resolution time-resolved imaging sequences [74,75]. Nonenhanced MRA techniques have used

relatively new technologies that show encouraging early results [76-79]. Further investigation of these methods is needed, particularly to improve diagnostic performance in calf and pedal vessels.

### Computed Tomography Angiography

Technological improvements in multidetector CTA, [80] combined with rapid image acquisition, lower radiation doses, lower complication rates, and 3-D volumetric imaging, when compared with DSA, yielded tremendous interest in its use as a noninvasive imaging tool for evaluating PAOD and lower-extremity arterial bypass grafts. Early studies suggested CTA was a viable substitute for DSA [81-88]. Multiple studies have demonstrated the accuracy of CTA for evaluating PAOD and have shown strong concordance between CTA and DSA for establishing an accurate treatment plan [89-96]. Willman et al [97] concluded that multidetector CTA was reliable and accurate, after using duplex US to assess lower-extremity bypasses to detect graft-related complications. Note that CTA accuracy decreases in severely stenotic lesions or smaller caliber vessels, particularly in heavily calcified vessels or areas adjacent to metallic artifact [86,95,98]. However, there is a potential for dual-energy CTA to exploit elemental attenuation changes and, hence, differentiate between calcium and iodine [99-101].

The choice between CTA and MRA for evaluating clinically suspected lower-extremity bypass grafts can be difficult. Both modalities are effective substitutes for DSA in terms of physician confidence and clinical outcomes, as demonstrated by Ouwendijk et al [102,103]. However, the choice of modality is often made by a combination of availability and user expertise.

### Summary

- Lower-extremity arterial bypass has been performed less frequently since the advent of effective endovascular techniques and aggressive medical management; however, it is still useful when either of these paths fail.
- Autogenous vein grafts have the highest patency rates, with the natural history of graft failure progressing from stenosis to thrombosis.
- Duplex US, ABI, and single-level pulse volume recording are adjuncts to clinical examination for the surveillance of asymptomatic grafts and can be particularly useful in suspected graft failure if prior examinations are available for comparison.
- DSA, MRA, and CTA are low-yield and unindicated examinations in an asymptomatic and otherwise well-functioning graft.
- MRA or CTA can confirm suspected abnormalities and are useful for treatment planning in cases of anticipated graft failure.
- Lower-extremity arteriography is best performed at the time of intervention.

### Anticipated Exceptions

Nephrogenic systemic fibrosis (NSF) is a disorder with a scleroderma-like presentation and a spectrum of manifestations that can range from limited clinical sequelae to fatality. It appears to be related to both underlying severe renal dysfunction and the administration of gadolinium-based contrast agents. It has occurred primarily in patients on dialysis, rarely in patients with very limited glomerular filtration rate (GFR) (ie, <30 mL/min/1.73m<sup>2</sup>), and almost never in other patients. There is growing literature regarding NSF. Although some controversy and lack of clarity remain, there is a consensus that it is advisable to avoid all gadolinium-based contrast agents in dialysis-dependent patients unless the possible benefits clearly outweigh the risk, and to limit the type and amount in patients with estimated GFR rates <30 mL/min/1.73m<sup>2</sup>. For more information, please see the [ACR Manual on Contrast Media](#) [104].

### Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults (see Table below). Additional

information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#) document.

Relative Radiation Level Designations		
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
○	0 mSv	0 mSv
⊕	<0.1 mSv	<0.03 mSv
⊕⊕	0.1-1 mSv	0.03-0.3 mSv
⊕⊕⊕	1-10 mSv	0.3-3 mSv
⊕⊕⊕⊕	10-30 mSv	3-10 mSv
⊕⊕⊕⊕⊕	30-100 mSv	10-30 mSv

\*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies”.

## Supporting Documents

- [ACR Appropriateness Criteria® Overview](#)
- [Procedure Information](#)
- [Evidence Table](#)

## References

1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *Eur J Vasc Endovasc Surg.* 2007;33 Suppl 1:S1-75.
2. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. *Lancet.* 2005;366(9501):1925-1934.
3. Hallett JW, Jr., Byrne J, Gayari MM, Ilstrup DM, Jacobsen SJ, Gray DT. Impact of arterial surgery and balloon angioplasty on amputation: a population-based study of 1155 procedures between 1973 and 1992. *J Vasc Surg.* 1997;25(1):29-38.
4. Tunis SR, Bass EB, Klag MJ, Steinberg EP. Variation in utilization of procedures for treatment of peripheral arterial disease. A look at patient characteristics. *Arch Intern Med.* 1993;153(8):991-998.
5. Tunis SR, Bass EB, Steinberg EP. The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease. *N Engl J Med.* 1991;325(8):556-562.
6. Johnson WC, Lee KK. A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization: a prospective randomized Department of Veterans Affairs cooperative study. *J Vasc Surg.* 2000;32(2):268-277.
7. Klinkert P, Post PN, Breslau PJ, van Bockel JH. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. *Eur J Vasc Endovasc Surg.* 2004;27(4):357-362.
8. Pereira CE, Albers M, Romiti M, Brochado-Neto FC, Pereira CA. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. *J Vasc Surg.* 2006;44(3):510-517.
9. Twine CP, McLain AD. Graft type for femoro-popliteal bypass surgery. *Cochrane Database Syst Rev.* 2010(5):CD001487.
10. Gupta AK, Bandyk DF, Cheanvechai D, Johnson BL. Natural history of infrainguinal vein graft stenosis relative to bypass grafting technique. *J Vasc Surg.* 1997;25(2):211-220; discussion 220-215.
11. Idu MM, Buth J, Hop WC, Cuypers P, van de Pavoordt ED, Tordoir JM. Factors influencing the development of vein-graft stenosis and their significance for clinical management. *Eur J Vasc Endovasc Surg.* 1999;17(1):15-21.

12. Wixon CL, Mills JL, Westerband A, Hughes JD, Ihnat DM. An economic appraisal of lower extremity bypass graft maintenance. *J Vasc Surg.* 2000;32(1):1-12.
13. Avino AJ, Bandyk DF, Gonsalves AJ, et al. Surgical and endovascular intervention for infrainguinal vein graft stenosis. *J Vasc Surg.* 1999;29(1):60-70; discussion 70-61.
14. Berkowitz HD, Fox AD, Deaton DH. Reversed vein graft stenosis: early diagnosis and management. *J Vasc Surg.* 1992;15(1):130-141; discussion 141-132.
15. Dougherty MJ, Calligaro KD, DeLaurentis DA. Revision of failing lower extremity bypass grafts. *Am J Surg.* 1998;176(2):126-130.
16. Landry GJ, Moneta GL, Taylor LM, Jr., Edwards JM, Yeager RA, Porter JM. Long-term outcome of revised lower-extremity bypass grafts. *J Vasc Surg.* 2002;35(1):56-62; discussion 62-53.
17. MacKenzie KS, Hill AB, Steinmetz OK. The predictive value of intraoperative duplex for early vein graft patency in lower extremity revascularization. *Ann Vasc Surg.* 1999;13(3):275-283.
18. Mills JL, Harris EJ, Taylor LM, Jr., Beckett WC, Porter JM. The importance of routine surveillance of distal bypass grafts with duplex scanning: a study of 379 reversed vein grafts. *J Vasc Surg.* 1990;12(4):379-386; discussion 387-379.
19. Carter A, Murphy MO, Halka AT, et al. The natural history of stenoses within lower limb arterial bypass grafts using a graft surveillance program. *Ann Vasc Surg.* 2007;21(6):695-703.
20. Rzucidlo EM, Walsh DB, Powell RJ, et al. Prediction of early graft failure with intraoperative completion duplex ultrasound scan. *J Vasc Surg.* 2002;36(5):975-981.
21. Barnes RW, Thompson BW, MacDonald CM, et al. Serial noninvasive studies do not herald postoperative failure of femoropopliteal or femorotibial bypass grafts. *Ann Surg.* 1989;210(4):486-493; discussion 493-484.
22. Berkowitz HD, Greenstein SM. Improved patency in reversed femoral-infrapopliteal autogenous vein grafts by early detection and treatment of the failing graft. *J Vasc Surg.* 1987;5(5):755-761.
23. Bandyk DF, Cato RF, Towne JB. A low flow velocity predicts failure of femoropopliteal and femorotibial bypass grafts. *Surgery.* 1985;98(4):799-809.
24. Bandyk DF, Kaebnick HW, Bergamini TM, Moldenhauer P, Towne JB. Hemodynamics of in situ saphenous vein arterial bypass. *Arch Surg.* 1988;123(4):477-482.
25. Bandyk DF, Kaebnick HW, Stewart GW, Towne JB. Durability of the in situ saphenous vein arterial bypass: a comparison of primary and secondary patency. *J Vasc Surg.* 1987;5(2):256-268.
26. Belkin M, Schwartz LB, Donaldson MC, Mannick JA, Whittemore AD. Hemodynamic impact of vein graft stenoses and their prediction in the vascular laboratory. *J Vasc Surg.* 1997;25(6):1016-1021; discussion 1022.
27. Mills JL, Fujitani RM, Taylor SM. The characteristics and anatomic distribution of lesions that cause reversed vein graft failure: a five-year prospective study. *J Vasc Surg.* 1993;17(1):195-204; discussion 204-196.
28. Treiman GS, Lawrence PF, Bhirangi K, Gazak CE. Effect of outflow level and maximum graft diameter on the velocity parameters of reversed vein bypass grafts. *J Vasc Surg.* 1999;30(1):16-25.
29. Weitzel WF, Kim K, Henke PK, Rubin JM. High-resolution ultrasound speckle tracking may detect vascular mechanical wall changes in peripheral artery bypass vein grafts. *Ann Vasc Surg.* 2009;23(2):201-206.
30. Ferris BL, Mills JL, Sr., Hughes JD, Durrani T, Knox R. Is early postoperative duplex scan surveillance of leg bypass grafts clinically important? *J Vasc Surg.* 2003;37(3):495-500.
31. Hobbs SD, Pinkney T, Sykes TC, Fox AD, Houghton AD. Patency of infra-inguinal vein grafts--effect of intraoperative Doppler assessment and a graft surveillance program. *J Vasc Surg.* 2009;49(6):1452-1458.
32. Mofidi R, Kelman J, Berry O, Bennett S, Murie JA, Dawson AR. Significance of the early postoperative duplex result in infrainguinal vein bypass surveillance. *Eur J Vasc Endovasc Surg.* 2007;34(3):327-332.
33. Wilson YG, Davies AH, Currie IC, et al. The value of pre-discharge Duplex scanning in infrainguinal graft surveillance. *Eur J Vasc Endovasc Surg.* 1995;10(2):237-242.
34. Lundell A, Lindblad B, Bergqvist D, Hansen F. Femoropopliteal-crural graft patency is improved by an intensive surveillance program: a prospective randomized study. *J Vasc Surg.* 1995;21(1):26-33; discussion 33-24.
35. Bergamini TM, George SM, Jr., Massey HT, et al. Intensive surveillance of femoropopliteal-tibial autogenous vein bypasses improves long-term graft patency and limb salvage. *Ann Surg.* 1995;221(5):507-515; discussion 515-506.

36. Davies AH, Hawdon AJ, Sydes MR, Thompson SG. Is duplex surveillance of value after leg vein bypass grafting? Principal results of the Vein Graft Surveillance Randomised Trial (VGST). *Circulation*. 2005;112(13):1985-1991.
37. Adam DJ, Gillies TE, Kelman J, Allan PL, Chalmers RT. Vascular surgical society of great britain and ireland: duplex surveillance does not enhance infrainguinal prosthetic bypass graft patency. *Br J Surg*. 1999;86(5):705.
38. Calligaro KD, Doerr K, McAfee-Bennett S, Krug R, Raviola CA, Dougherty MJ. Should duplex ultrasonography be performed for surveillance of femoropopliteal and femorotibial arterial prosthetic bypasses? *Ann Vasc Surg*. 2001;15(5):520-524.
39. Hoballah JJ, Nazzal MM, Ryan SM, et al. Is color duplex surveillance of infrainguinal polytetrafluoroethylene grafts worthwhile? *Am J Surg*. 1997;174(2):131-135.
40. Ihlberg L, Luther M, Tierala E, Lepantalo M. The utility of duplex scanning in infrainguinal vein graft surveillance: results from a randomised controlled study. *Eur J Vasc Endovasc Surg*. 1998;16(1):19-27.
41. Landry GJ, Moneta GL, Taylor LM, Jr., et al. Duplex scanning alone is not sufficient imaging before secondary procedures after lower extremity reversed vein bypass graft. *J Vasc Surg*. 1999;29(2):270-280; discussion 280-271.
42. Toursarkissian B, D'Ayala M, Shireman PK, Schoolfield J, Sykes MT. Lower extremity bypass graft revision in diabetics. *Vasc Surg*. 2001;35(5):369-377.
43. Balduf LM, Langsfeld M, Marek JM, Tullis MJ, Kasirajan K, Matteson B. Complication rates of diagnostic angiography performed by vascular surgeons. *Vasc Endovascular Surg*. 2002;36(6):439-445.
44. Singh H, Cardella JF, Cole PE, et al. Quality improvement guidelines for diagnostic arteriography. *J Vasc Interv Radiol*. 2003;14(9 Pt 2):S283-288.
45. Ersoy H, Rybicki FJ. MR angiography of the lower extremities. *AJR Am J Roentgenol*. 2008;190(6):1675-1684.
46. Hadizadeh DR, Gieseke J, Lohmaier SH, et al. Peripheral MR angiography with blood pool contrast agent: prospective intraindividual comparative study of high-spatial-resolution steady-state MR angiography versus standard-resolution first-pass MR angiography and DSA. *Radiology*. 2008;249(2):701-711.
47. Ho VB, Corse WR. MR angiography of the abdominal aorta and peripheral vessels. *Radiol Clin North Am*. 2003;41(1):115-144.
48. Koelemay MJ, Lijmer JG, Stoker J, Legemate DA, Bossuyt PM. Magnetic resonance angiography for the evaluation of lower extremity arterial disease: a meta-analysis. *Jama*. 2001;285(10):1338-1345.
49. Menke J, Larsen J. Meta-analysis: Accuracy of contrast-enhanced magnetic resonance angiography for assessing steno-occlusions in peripheral arterial disease. *Ann Intern Med*. 2010;153(5):325-334.
50. Tatli S, Lipton MJ, Davison BD, Skorstad RB, Yucel EK. From the RSNA refresher courses: MR imaging of aortic and peripheral vascular disease. *Radiographics*. 2003;23 Spec No:S59-78.
51. Andreisek G, Pfammatter T, Goepfert K, et al. Peripheral arteries in diabetic patients: standard bolus-chase and time-resolved MR angiography. *Radiology*. 2007;242(2):610-620.
52. Lapeyre M, Kobeiter H, Desgranges P, Rahmouni A, Becquemin JP, Luciani A. Assessment of critical limb ischemia in patients with diabetes: comparison of MR angiography and digital subtraction angiography. *AJR Am J Roentgenol*. 2005;185(6):1641-1650.
53. Zhang HL, Khilnani NM, Prince MR, et al. Diagnostic accuracy of time-resolved 2D projection MR angiography for symptomatic infrapopliteal arterial occlusive disease. *AJR Am J Roentgenol*. 2005;184(3):938-947.
54. Hakyemez B, Koroglu M, Yildiz H, Erdogan C, Atasoy S, Yurdaeken K. Table-moving contrast-enhanced magnetic resonance angiography in the evaluation of lower extremity peripheral arterial bypass grafts. *JBR-BTR*. 2006;89(2):67-71.
55. Bendib K, Berthezenne Y, Croisille P, Villard J, Douek PC. Assessment of complicated arterial bypass grafts: value of contrast-enhanced subtraction magnetic resonance angiography. *J Vasc Surg*. 1997;26(6):1036-1042.
56. Dorenbeck U, Seitz J, Volk M, et al. Evaluation of arterial bypass grafts of the pelvic and lower extremities with gadolinium-enhanced magnetic resonance angiography: comparison with digital subtraction angiography. *Invest Radiol*. 2002;37(2):60-64.
57. Loewe C, Cejna M, Lammer J, Thurnher SA. Contrast-enhanced magnetic resonance angiography in the evaluation of peripheral bypass grafts. *Eur Radiol*. 2000;10(5):725-732.

58. Loewe C, Cejna M, Schoder M, et al. Contrast material-enhanced, moving-table MR angiography versus digital subtraction angiography for surveillance of peripheral arterial bypass grafts. *J Vasc Interv Radiol.* 2003;14(9 Pt 1):1129-1137.
59. Reid SK, Pagan-Marin HR, Menzoian JO, Woodson J, Yucel EK. Contrast-enhanced moving-table MR angiography: prospective comparison to catheter arteriography for treatment planning in peripheral arterial occlusive disease. *J Vasc Interv Radiol.* 2001;12(1):45-53.
60. Bertschinger K, Cassina PC, Debatin JF, Ruehm SG. Surveillance of peripheral arterial bypass grafts with three-dimensional MR angiography: comparison with digital subtraction angiography. *AJR Am J Roentgenol.* 2001;176(1):215-220.
61. Meissner OA, Verrel F, Tato F, et al. Magnetic resonance angiography in the follow-up of distal lower-extremity bypass surgery: comparison with duplex ultrasound and digital subtraction angiography. *J Vasc Interv Radiol.* 2004;15(11):1269-1277.
62. Mitsouras D, Mulkern RV, Owens CD, et al. High-resolution peripheral vein bypass graft wall studies using high sampling efficiency inner volume 3D FSE. *Magn Reson Med.* 2008;59(3):650-654.
63. Mitsouras D, Owens CD, Conte MS, et al. In vivo differentiation of two vessel wall layers in lower extremity peripheral vein bypass grafts: application of high-resolution inner-volume black blood 3D FSE. *Magn Reson Med.* 2009;62(3):607-615.
64. Rybicki FJ, Mitsouras D, Owens CD, et al. Multi-contrast high spatial resolution black blood inner volume three-dimensional fast spin echo MR imaging in peripheral vein bypass grafts. *Int J Cardiovasc Imaging.* 2010;26(6):683-691.
65. Bonel HM, Saar B, Hoppe H, et al. MR angiography of infrapopliteal arteries in patients with peripheral arterial occlusive disease by using Gadofosveset at 3.0 T: diagnostic accuracy compared with selective DSA. *Radiology.* 2009;253(3):879-890.
66. Bosch E, Kreitner KF, Peirano MF, Thurnher S, Shamsi K, Parsons EC, Jr. Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: multicenter comparative phase 3 study. *AJR Am J Roentgenol.* 2008;190(1):179-186.
67. Hentsch A, Aschauer MA, Balzer JO, et al. Gadobutrol-enhanced moving-table magnetic resonance angiography in patients with peripheral vascular disease: a prospective, multi-centre blinded comparison with digital subtraction angiography. *Eur Radiol.* 2003;13(9):2103-2114.
68. Kos S, Reisinger C, Aschwanden M, Bongartz GM, Jacob AL, Bilecen D. Pedal angiography in peripheral arterial occlusive disease: first-pass i.v. contrast-enhanced MR angiography with blood pool contrast medium versus intraarterial digital subtraction angiography. *AJR Am J Roentgenol.* 2009;192(3):775-784.
69. Kreitner KF, Kunz RP, Herber S, Martenstein S, Dorweiler B, Dueber C. MR angiography of the pedal arteries with gadobenate dimeglumine, a contrast agent with increased relaxivity, and comparison with selective intraarterial DSA. *J Magn Reson Imaging.* 2008;27(1):78-85.
70. Rohrl B, Kunz RP, Oberholzer K, et al. Gadofosveset-enhanced MR angiography of the pedal arteries in patients with diabetes mellitus and comparison with selective intraarterial DSA. *Eur Radiol.* 2009;19(12):2993-3001.
71. Thurnher S, Miller S, Schneider G, et al. Diagnostic performance of gadobenate dimeglumine enhanced MR angiography of the iliofemoral and calf arteries: a large-scale multicenter trial. *AJR Am J Roentgenol.* 2007;189(5):1223-1237.
72. Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. *J Magn Reson Imaging.* 2007;26(5):1190-1197.
73. Miyazaki M, Lee VS. Nonenhanced MR angiography. *Radiology.* 2008;248(1):20-43.
74. Attenberger UI, Haneder S, Morelli JN, Diehl SJ, Schoenberg SO, Michaely HJ. Peripheral arterial occlusive disease: evaluation of a high spatial and temporal resolution 3-T MR protocol with a low total dose of gadolinium versus conventional angiography. *Radiology.* 2010;257(3):879-887.
75. Nael K, Moriarty JM, Finn JP. Low dose CE-MRA. *Eur J Radiol.* 2011;80(1):2-8.
76. Gutzeit A, Sutter R, Froehlich JM, et al. ECG-triggered non-contrast-enhanced MR angiography (TRANCE) versus digital subtraction angiography (DSA) in patients with peripheral arterial occlusive disease of the lower extremities. *Eur Radiol.* 2011;21(9):1979-1987.
77. Hodnett PA, Koktzoglou I, Davarpanah AH, et al. Evaluation of peripheral arterial disease with nonenhanced quiescent-interval single-shot MR angiography. *Radiology.* 2011;260(1):282-293.

78. Li D, Lin J, Yan F, et al. Unenhanced calf MR angiography at 3.0 T using electrocardiography-gated partial-fourier fast spin echo imaging with variable flip angle. *Eur Radiol*. 2011;21(6):1311-1322.
79. Mell M, Tefera G, Thornton F, Siepman D, Turnipseed W. Clinical utility of time-resolved imaging of contrast kinetics (TRICKS) magnetic resonance angiography for infrageniculate arterial occlusive disease. *J Vasc Surg*. 2007;45(3):543-548; discussion 548.
80. Kumamaru KK, Hoppel BE, Mather RT, Rybicki FJ. CT angiography: current technology and clinical use. *Radiol Clin North Am*. 2010;48(2):213-235, vii.
81. Heijenbrok-Kal MH, Kock MC, Hunink MG. Lower extremity arterial disease: multidetector CT angiography meta-analysis. *Radiology*. 2007;245(2):433-439.
82. Met R, Bipat S, Legemate DA, Reekers JA, Koelemay MJ. Diagnostic performance of computed tomography angiography in peripheral arterial disease: a systematic review and meta-analysis. *Jama*. 2009;301(4):415-424.
83. Catalano C, Fraioli F, Laghi A, et al. Infrarenal aortic and lower-extremity arterial disease: diagnostic performance of multi-detector row CT angiography. *Radiology*. 2004;231(2):555-563.
84. Godshall CJ. Computed tomographic angiography allows accurate planning of the setting and technique of open and percutaneous vascular interventions. *Am J Surg*. 2005;190(2):218-220.
85. Martin ML, Tay KH, Flak B, et al. Multidetector CT angiography of the aortoiliac system and lower extremities: a prospective comparison with digital subtraction angiography. *AJR Am J Roentgenol*. 2003;180(4):1085-1091.
86. Ofer A, Nitecki SS, Linn S, et al. Multidetector CT angiography of peripheral vascular disease: a prospective comparison with intraarterial digital subtraction angiography. *AJR Am J Roentgenol*. 2003;180(3):719-724.
87. Rubin GD, Schmidt AJ, Logan LJ, Sofilos MC. Multi-detector row CT angiography of lower extremity arterial inflow and runoff: initial experience. *Radiology*. 2001;221(1):146-158.
88. Soto JA, Munera F, Morales C, et al. Focal arterial injuries of the proximal extremities: helical CT arteriography as the initial method of diagnosis. *Radiology*. 2001;218(1):188-194.
89. Napoli A, Anzidei M, Zaccagna F, et al. Peripheral arterial occlusive disease: diagnostic performance and effect on therapeutic management of 64-section CT angiography. *Radiology*. 2011;261(3):976-986.
90. Schernthaner R, Fleischmann D, Stadler A, Schernthaner M, Lammer J, Loewe C. Value of MDCT angiography in developing treatment strategies for critical limb ischemia. *AJR Am J Roentgenol*. 2009;192(5):1416-1424.
91. Schernthaner R, Stadler A, Lemoschitz F, et al. Multidetector CT angiography in the assessment of peripheral arterial occlusive disease: accuracy in detecting the severity, number, and length of stenoses. *Eur Radiol*. 2008;18(4):665-671.
92. Shareghi S, Gopal A, Gul K, et al. Diagnostic accuracy of 64 multidetector computed tomographic angiography in peripheral vascular disease. *Catheter Cardiovasc Interv*. 2010;75(1):23-31.
93. Albrecht T, Foert E, Holtkamp R, et al. 16-MDCT angiography of aortoiliac and lower extremity arteries: comparison with digital subtraction angiography. *AJR Am J Roentgenol*. 2007;189(3):702-711.
94. Ota H, Takase K, Igarashi K, et al. MDCT compared with digital subtraction angiography for assessment of lower extremity arterial occlusive disease: importance of reviewing cross-sectional images. *AJR Am J Roentgenol*. 2004;182(1):201-209.
95. Schernthaner R, Fleischmann D, Lemoschitz F, Stadler A, Lammer J, Loewe C. Effect of MDCT angiographic findings on the management of intermittent claudication. *AJR Am J Roentgenol*. 2007;189(5):1215-1222.
96. Willmann JK, Baumert B, Schertler T, et al. Aortoiliac and lower extremity arteries assessed with 16-detector row CT angiography: prospective comparison with digital subtraction angiography. *Radiology*. 2005;236(3):1083-1093.
97. Willmann JK, Mayer D, Banyai M, et al. Evaluation of peripheral arterial bypass grafts with multi-detector row CT angiography: comparison with duplex US and digital subtraction angiography. *Radiology*. 2003;229(2):465-474.
98. Ouwendijk R, Kock MC, van Dijk LC, van Sambeek MR, Stijnen T, Hunink MG. Vessel wall calcifications at multi-detector row CT angiography in patients with peripheral arterial disease: effect on clinical utility and clinical predictors. *Radiology*. 2006;241(2):603-608.
99. Brockmann C, Jochum S, Sadick M, et al. Dual-energy CT angiography in peripheral arterial occlusive disease. *Cardiovasc Interv Radiol*. 2009;32(4):630-637.

100. Johnson TR, Krauss B, Sedlmair M, et al. Material differentiation by dual energy CT: initial experience. *Eur Radiol*. 2007;17(6):1510-1517.
101. Meyer BC, Werncke T, Hopfenmuller W, Raatschen HJ, Wolf KJ, Albrecht T. Dual energy CT of peripheral arteries: effect of automatic bone and plaque removal on image quality and grading of stenoses. *Eur J Radiol*. 2008;68(3):414-422.
102. Ouwendijk R, de Vries M, Pattynama PM, et al. Imaging peripheral arterial disease: a randomized controlled trial comparing contrast-enhanced MR angiography and multi-detector row CT angiography. *Radiology*. 2005;236(3):1094-1103.
103. Ouwendijk R, de Vries M, Stijnen T, et al. Multicenter randomized controlled trial of the costs and effects of noninvasive diagnostic imaging in patients with peripheral arterial disease: the DIPAD trial. *AJR Am J Roentgenol*. 2008;190(5):1349-1357.
104. American College of Radiology. *Manual on Contrast Media*. Available at: [http://www.acr.org/~link.aspx?\\_id=29C40D1FE0EC4E5EAB6861BD213793E5&z=z](http://www.acr.org/~link.aspx?_id=29C40D1FE0EC4E5EAB6861BD213793E5&z=z).

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.